Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018

Details for Mechanism ID: 18269
Country/Region: Haiti
Year: 2016
Main Partner: GHESKIO
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,795,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $418,841
Care: TB/HIV (HVTB) $136,162
Care: Pediatric Care and Support (PDCS) $153,967
Strategic Information (HVSI) $55,000
Testing: HIV Testing and Counseling (HVCT) $734,462
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $300,000
Treatment: Adult Treatment (HTXS) $2,712,850
Treatment: Pediatric Treatment (PDTX) $283,718
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 86
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 13
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 119
GEND_GBV Number of people receiving post-GBV care 2017 132
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 8,285
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 8,285
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 78,137
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 56,579
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 151,286
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,411
HTS_TST Service Delivery Point (Facility): Outpatient 2017 1,521
HTS_TST Service Delivery Point (Facility): Pediatric 2017 15,046
HTS_TST Service Delivery Point (Facility): PMTCT 2017 20,702
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,540
HTS_TST Service Delivery Point (Facility): VCT 2017 110,066
HTS_TST Sum of Aggregated Age/Sex <15 2017 16,570
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 134,716
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 151,286
HTS_TST Test Result by Aggregated Age and Sex: Negative <15 Female 2017 4,898
HTS_TST Test Result by Aggregated Age and Sex: Negative <15 Male 2017 3,673
HTS_TST Test Result by Aggregated Age and Sex: Negative 15+ Female 2017 73,478
HTS_TST Test Result by Aggregated Age and Sex: Negative 15+ Male 2017 40,414
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 133
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 133
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 3,540
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,561
PMTCT_ART Already on ART at beginning of current pregnancy 2017 185
PMTCT_ART New on ART 2017 200
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 20,702
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 215
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 169
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 9
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 13
PMTCT_EID Sum of Infant Age disaggregates 2017 384
PMTCT_STAT By: Known positives at entry 2017 220
PMTCT_STAT By: Number of new positives identified 2017 186
PMTCT_STAT Number of new ANC and L&D clients 2017 21,168
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 20,702
PMTCT_STAT Sum of Positives Status disaggregates 2017 406
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 10
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 234
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 6
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 158
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 408
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 408
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 373
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 112
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 373
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 56
TB_SCREENDX Screen Result: Screened Positive for TB 2017 373
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 9,946
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 6,629
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 440
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 295
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 17,310
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 72
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,449
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 48
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 968
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 2,537
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 3,001
TX_CURR Aggregated Age/Sex: <15 Female 2017 440
TX_CURR Aggregated Age/Sex: <15 Male 2017 295
TX_CURR Aggregated Age/Sex: 15+ Female 2017 9,946
TX_CURR Aggregated Age/Sex: 15+ Male 2017 6,629
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 17,310
TX_CURR Sum of Aggregated Age/Sex <15 2017 735
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 16,575
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 17,310
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 103
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 103
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 3,190
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 2,308
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 5,704
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 5,704
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 17,310
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 12,981
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 330
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 218
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 7,459
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 4,974
TX_PVLS Numerator: Indication: Routine 2017 11,688
TX_PVLS Numerator: Indication: Targeted 2017 1,293
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 440
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 295
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 9,946
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 6,629
TX_PVLS_den Denominator: Indication: Routine 2017 15,581
TX_PVLS_den Denominator: Indication: Targeted 2017 1,729
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 66
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 44
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,328
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 775
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,213
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,848
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 86
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 57
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,708
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 997
Cross Cutting Budget Categories and Known Amounts Total: $3,215,000
Motor Vehicles: Purchased $60,000
Human Resources for Health $3,000,000
Gender: Gender Based Violence (GBV) $100,000
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Key Populations: Sex Workers $30,000
Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG $25,000
Collection and use of strategic information